Postbiotics as effective and safe "vaccines" against various respiratory diseases: literature review
DOI:
https://doi.org/10.12775/QS.2026.54.70813Keywords
bacterial lysate, asthma, COPD, gut-lung axis, allergic rhinitis, respiratory tract infectionsAbstract
Background: Respiratory diseases, including COPD, asthma, and allergic rhinitis, pose a significant health and economic burden, prompting the search for new preventive and therapeutic strategies. Increasing attention is paid to microbiome-based therapies and the gut-lung axis as targets for immunomodulatory interventions. Postbiotics - defined as non-viable microorganisms or their components that exert beneficial biological effects - have emerged as a promising area of research.
Aim of the study: This study presented the current state of knowledge regarding postbiotics and assessed their potential in the prevention and treatment of respiratory diseases, with particular emphasis on their mechanisms of action.
Methodology: The review was conducted using PubMed and supplementary Google Scholar. Studies from 2012 to 2026 were analyzed.
Results: Postbiotics demonstrate multiple mechanisms of action, including modulation of the immune response, regulation of cytokine production, influence on the Th1/Th2 balance, and enhancement of epithelial barrier integrity. Experimental and clinical evidence suggests that postbiotics may reduce the frequency and severity of infections, decrease exacerbations of chronic respiratory diseases, and support the treatment of atopic and neaplastic conditions. In addition, they have a favorable safety profile, potentially better than probiotics, especially in populations with compromised immunity.
Conclusion: Postbiotics represent a diverse and promising group of compounds with significant potential for both preventive and therapeutic applications in respiratory diseases. However, further well-designed, large-scale clinical trials are necessary to confirm their efficacy and safety.
References
[1] Z. Cao et al., “Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2021: results from the Global Burden of Disease Study 2021,” BMJ Public Health, vol. 4, no. 1, p. e002489, Jan. 2026, doi: 10.1136/bmjph-2024-002489. https://doi.org/10.1136/bmjph-2024-002489.
[2] S. Chen et al., “The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study.,” Lancet Glob. Health, vol. 11, no. 8, pp. e1183–e1193, Aug. 2023, doi: 10.1016/S2214-109X(23)00217-6. https://doi.org/10.1016/S2214-109X(23)00217-6.
[3] S. Salminen et al., “The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics,” Sep. 01, 2021, Nature Research. doi: 10.1038/s41575-021-00440-6. https://doi.org/10.1038/s41575-021-00440-6.
[4] J. E. Aguilar-Toalá et al., “Postbiotics: An evolving term within the functional foods field,” Trends Food Sci. Technol., vol. 75, pp. 105–114, May 2018, doi: 10.1016/j.tifs.2018.03.009. https://doi.org/10.1016/j.tifs.2018.03.009.
[5] A. Kaczynska, M. Klosinska, P. Chmiel, K. Janeczek, and A. Emeryk, “The Crosstalk between the Gut Microbiota Composition and the Clinical Course of Allergic Rhinitis: The Use of Probiotics, Prebiotics and Bacterial Lysates in the Treatment of Allergic Rhinitis.,” Nutrients, vol. 14, no. 20, Oct. 2022, doi: 10.3390/nu14204328. https://doi.org/10.3390/nu14204328.
[6] G. Vinderola, M. E. Sanders, S. Salminen, and H. Szajewska, “Postbiotics: The concept and their use in healthy populations,” Front. Nutr., vol. 9, Dec. 2022, doi: 10.3389/fnut.2022.1002213. https://doi.org/10.3389/fnut.2022.1002213
[7] A. Kumar, K. M. Green, and M. Rawat, “A Comprehensive Overview of Postbiotics with a Special Focus on Discovery Techniques and Clinical Applications,” Sep. 01, 2024, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/foods13182937. https://doi.org/10.3390/foods13182937
[8] L. Rebolledo et al., “Bacterial immunotherapy is highly effective in reducing recurrent upper respiratory tract infections in children: a prospective observational study,” European Archives of Oto-Rhino-Laryngology, vol. 280, no. 10, pp. 4519–4530, Oct. 2023, doi: 10.1007/s00405-023-08035-4. https://doi.org/10.1007/s00405-023-08035-4
[9] F. Ferrara, A. Rial, N. Suárez, and J. A. Chabalgoity, “Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation,” Front. Immunol., vol. 12, Apr. 2021, doi: 10.3389/fimmu.2021.562244. https://doi.org/10.3389/fimmu.2021.562244
[10] Humaira, I. Ahmad, H. A. Shakir, M. Khan, M. Franco, and M. Irfan, “Bacterial Extracellular Vesicles: Potential Therapeutic Applications, Challenges, and Future Prospects.,” J. Basic Microbiol., vol. 64, no. 10, p. e2400221, Oct. 2024, doi: 10.1002/jobm.202400221. https://doi.org/10.1002/jobm.202400221
[11] A. Razim et al., “Bacterial extracellular vesicles as intranasal postbiotics: Detailed characterization and interaction with airway cells,” J. Extracell. Vesicles, vol. 13, no. 10, Oct. 2024, doi: 10.1002/jev2.70004. https://doi.org/10.1002/jev2.70004
[12] L. M. Muñoz-Echeverri, S. Benavides-López, O. Geiger, M. A. Trujillo-Roldán, and N. A. Valdez-Cruz, “Bacterial extracellular vesicles: biotechnological perspective for enhanced productivity.,” World J. Microbiol. Biotechnol., vol. 40, no. 6, p. 174, Apr. 2024, doi: 10.1007/s11274-024-03963-7. https://doi.org/10.1007/s11274-024-03963-7
[13] C. A. M. Wegh, S. Y. Geerlings, J. Knol, G. Roeselers, and C. Belzer, “Postbiotics and their potential applications in early life nutrition and beyond,” Oct. 01, 2019, MDPI AG. doi: 10.3390/ijms20194673. https://doi.org/10.3390/ijms20194673
[14] F. Braido et al., “Sublingually administered bacterial lysates: rationale, mechanisms of action and clinical outcomes,” 2024, Bioexcel Publishing LTD. doi: 10.7573/dic.2024-1-5. https://doi.org/10.7573/dic.2024-1-5
[15] S. Werellagama et al., “Host-directed broad-spectrum immunotherapeutic strategy for respiratory infections: Heat-killed Caulobacter crescentus (HKCC) as an innate-immune based biotherapeutic/postbiotic,” PLoS Pathog., vol. 22, no. 2 February, Feb. 2026, doi: 10.1371/journal.ppat.1013994. https://doi.org/10.1371/journal.ppat.1013994
[16] Y. K. Lee, J. H. Haam, E. Suh, S. H. Cho, and Y. S. Kim, “A Case-Control Study on the Changes in Natural Killer Cell Activity following Administration of Polyvalent Mechanical Bacterial Lysate in Korean Adults with Recurrent Respiratory Tract Infection,” J. Clin. Med., vol. 11, no. 11, Jun. 2022, doi: 10.3390/jcm11113014. https://doi.org/10.3390/jcm11113014
[17] K. Janeczek et al., “Effect of immunostimulation with bacterial lysate on the clinical course of allergic rhinitis and the level of γδT, iNKT and cytotoxic T cells in children sensitized to grass pollen allergens: A randomized controlled trial,” Front. Immunol., vol. 14, Jan. 2023, doi: 10.3389/fimmu.2023.1073788. https://doi.org/10.3389/fimmu.2023.1073788
[18] M. Bartkowiak-Emeryk, A. Emeryk, J. Roliński, E. Wawryk-Gawda, and E. Markut-Miotła, “Impact of Polyvalent Mechanical Bacterial Lysate on lymphocyte number and activity in asthmatic children: a randomized controlled trial,” Allergy, Asthma and Clinical Immunology, vol. 17, no. 1, Dec. 2021, doi: 10.1186/s13223-020-00503-4. https://doi.org/10.1186/s13223-020-00503-4
[19] X. Chen, C. Yuan, J. He, W. Li, and C. Liao, “Current research status and trends in the bioactivity of postbiotics,” 2025, Frontiers Media SA. doi: 10.3389/frfst.2025.1692683. https://doi.org/10.3389/frfst.2025.1692683
[20] D. Merenstein et al., “Emerging issues in probiotic safety: 2023 perspectives,” 2023, Taylor and Francis Ltd. doi: 10.1080/19490976.2023.2185034. https://doi.org/10.1080/19490976.2023.2185034
[21] H. Szajewska et al., “Antibiotic-perturbed microbiota and the role of probiotics.,” Nat. Rev. Gastroenterol. Hepatol., vol. 22, no. 3, pp. 155–172, Mar. 2025, doi: 10.1038/s41575-024-01023-x. https://doi.org/10.1038/s41575-024-01023-x
[22] S. Smolinska, F.-D. Popescu, and M. Zemelka-Wiacek, “A Review of the Influence of Prebiotics, Probiotics, Synbiotics, and Postbiotics on the Human Gut Microbiome and Intestinal Integrity.,” J. Clin. Med., vol. 14, no. 11, May 2025, doi: 10.3390/jcm14113673. https://doi.org/10.3390/jcm14113673
[23] A. Vitiello, M. Boccellino, and A. Zovi, “Probiotics and postbiotics to counter antimicrobial resistant infections, an editorial,” European Journal of Clinical Microbiology and Infectious Diseases, Mar. 2025, doi: 10.1007/s10096-025-05371-7. https://doi.org/10.1007/s10096-025-05371-7
[24] C. Porsbjerg, E. Melén, L. Lehtimäki, and D. Shaw, “Asthma,” The Lancet, vol. 401, no. 10379, pp. 858–873, Mar. 2023, doi: 10.1016/S0140-6736(22)02125-0. https://doi.org/10.1016/S0140-6736(22)02125-0
[25] L. Yuan et al., “Global, regional, national burden of asthma from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021,” EClinicalMedicine, vol. 80, Feb. 2025, doi: 10.1016/j.eclinm.2024.103051. https://doi.org/10.1016/j.eclinm.2024.103051
[26] E. Garcia and F. Gilliland, “Moving beyond medication: Assessment and interventions on environmental and social determinants are needed to reduce severe asthma,” Feb. 01, 2022, Elsevier Inc. doi: 10.1016/j.jaci.2021.12.760. https://doi.org/10.1016/j.jaci.2021.12.760
[27] K. Węgrzyn, A. Jasińska, K. Janeczek, and W. Feleszko, “The Role of Postbiotics in Asthma Treatment,” Aug. 01, 2024, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/microorganisms12081642. https://doi.org/10.3390/microorganisms12081642
[28] L. Li et al., “Effectiveness of polyvalent bacterial lysate for pediatric asthma control: a retrospective propensity score-matched cohort study,” Transl. Pediatr., vol. 11, no. 10, pp. 1697–1703, Oct. 2022, doi: 10.21037/tp-22-489. https://doi.org/10.21037/tp-22-489
[29] S. Yao, R. Qin, X. Song, L. He, X. Lin, and J. Li, “Bacterial lysate add-on therapy in adult and childhood asthma: a systematic review and meta-analysis,” J. Thorac. Dis., vol. 15, no. 6, pp. 3143–3157, Jun. 2023, doi: 10.21037/jtd-22-1469. https://doi.org/10.21037/jtd-22-1469
[30] M. E. Christopoulou et al., “Oral Bacterial Lysate OM-85 Prevents Respiratory Tract Infections in Asthma: The OMRIA RWE Study,” J. Asthma Allergy, vol. 18, pp. 891–902, 2025, doi: 10.2147/JAA.S517194. https://doi.org/10.2147/JAA.S517194
[31] S. M. Nur Husna, H. T. T. Tan, N. Md Shukri, N. S. Mohd Ashari, and K. K. Wong, “Allergic Rhinitis: A Clinical and Pathophysiological Overview,” Apr. 07, 2022, Frontiers Media S.A. doi: 10.3389/fmed.2022.874114. https://doi.org/10.3389/fmed.2022.874114
[32] T. Ozdoganoglu and M. Songu, “The burden of allergic rhinitis and asthma,” 2012. doi: 10.1177/1753465811431975. https://doi.org/10.1177/1753465811431975
[33] K. Janeczek, A. Kaczyńska, A. Emeryk, and C. Cingi, “Perspectives for the Use of Bacterial Lysates for the Treatment of Allergic Rhinitis: A Systematic Review,” 2022, Dove Medical Press Ltd. doi: 10.2147/JAA.S360828. https://doi.org/10.2147/JAA.S360828
[34] K. Janeczek, A. Emeryk, Ł. Zimmer, E. Poleszak, and M. Ordak, “Nasal carriage of Staphylococcus aureus in children with grass pollen-induced allergic rhinitis and the effect of polyvalent mechanical bacterial lysate immunostimulation on carriage status: A randomized controlled trial,” Immun. Inflamm. Dis., vol. 10, no. 3, Mar. 2022, doi: 10.1002/iid3.584. https://doi.org/10.1002/iid3.584
[35] M. M. de Oca et al., “The global burden of COPD: epidemiology and effect of prevention strategies,” Aug. 01, 2025, Elsevier Ltd. doi: 10.1016/S2213-2600(24)00339-4. https://doi.org/10.1016/S2213-2600(24)00339-4
[36] J. Xu, Q. Zeng, S. Li, Q. Su, and H. Fan, “Inflammation mechanism and research progress of COPD,” 2024, Frontiers Media SA. doi: 10.3389/fimmu.2024.1404615. https://doi.org/10.3389/fimmu.2024.1404615
[37] B. K. Shah, B. Singh, Y. Wang, S. Xie, and C. Wang, “Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment,” 2023, Hindawi Limited. doi: 10.1155/2023/8840594. https://doi.org/10.1155/2023/8840594
[38] D. Du et al., “The availability of drugs for stable COPD treatment in China: a cross-sectional survey,” NPJ Prim. Care Respir. Med., vol. 35, no. 1, Dec. 2025, doi: 10.1038/s41533-025-00413-1. https://doi.org/10.1038/s41533-025-00413-1
[39] G. Troiano, G. Messina, and N. Nante, “Bacterial lysates (OM-85 BV): A cost-effective proposal in order to contrast antibiotic resistance,” J. Prev. Med. Hyg., vol. 62, no. 2, pp. E564–E573, Jul. 2021, doi: 10.15167/2421-4248/jpmh2021.62.2.1734. https://doi.org/10.15167/2421-4248/jpmh2021.62.2.1734
[40] J. Y. Choi, Y. B. Park, T. J. An, K. H. Yoo, and C. K. Rhee, “Effect of Broncho-Vaxom (OM-85) on the frequency of chronic obstructive pulmonary disease (COPD) exacerbations,” BMC Pulm. Med., vol. 23, no. 1, Dec. 2023, doi: 10.1186/s12890-023-02665-4. https://doi.org/10.1186/s12890-023-02665-4
[41] M. Di Gioacchino, F. Santilli, and A. Pession, “Is There a Role for Immunostimulant Bacterial Lysates in the Management of Respiratory Tract Infection?,” Oct. 01, 2024, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/biom14101249. https://doi.org/10.3390/biom14101249
[42] M. M. Rahman, I. D. Grice, G. C. Ulett, and M. Q. Wei, “Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer,” 2024, Hindawi Limited. doi: 10.1155/2024/4312908. https://doi.org/10.1155/2024/4312908
[43] J. Żółkiewicz, A. Marzec, M. Ruszczyński, and W. Feleszko, “Postbiotics-A Step Beyond Pre- and Probiotics.,” Nutrients, vol. 12, no. 8, Jul. 2020, doi: 10.3390/nu12082189. https://doi.org/10.3390/nu12082189
[44] K. H. Antunes et al., “Airway Administration of Bacterial Lysate OM-85 Protects Mice Against Respiratory Syncytial Virus Infection,” Front. Immunol., vol. 13, May 2022, doi: 10.3389/fimmu.2022.867022. https://doi.org/10.3389/fimmu.2022.867022
[45] S. D. Todorov, J. R. Tagg, and I. V. Ivanova, “Could Probiotics and Postbiotics Function as ‘Silver Bullet’ in the Post-COVID-19 Era?,” Dec. 01, 2021, Springer. doi: 10.1007/s12602-021-09833-0. https://doi.org/10.1007/s12602-021-09833-0
[46] L. Lv et al., “The faecal metabolome in COVID-19 patients is altered and associated with clinical features and gut microbes,” Anal. Chim. Acta, vol. 1152, Apr. 2021, doi: 10.1016/j.aca.2021.338267. https://doi.org/10.1016/j.aca.2021.338267
[47] S. M. Petrut, A. M. Bragaru, A. E. Munteanu, A. D. Moldovan, C. A. Moldovan, and E. Rusu, “Gut over Mind: Exploring the Powerful Gut–Brain Axis,” Mar. 01, 2025, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/nu17050842. https://doi.org/10.3390/nu17050842
[48] M. E. Jach et al., “The Role of Probiotics and Their Postbiotic Metabolites in Post-COVID-19 Syndrome,” Oct. 01, 2025, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/molecules30204130. https://doi.org/10.3390/molecules30204130
[49] Q. Luo and D. P. Smith, “Global cancer burden: progress, projections, and challenges,” Oct. 11, 2025, Elsevier B.V. doi: 10.1016/S0140-6736(25)01570-3. https://doi.org/10.1016/S0140-6736(25)01570-3
[50] M. Sun et al., “OM-85, a Bacterial Lysate, Reduces Pulmonary Nodule Malignant Probability: A Retrospective Study,” Clinical Respiratory Journal, vol. 19, no. 7, Jul. 2025, doi: 10.1111/crj.70109. https://doi.org/10.1111/crj.70109
[51] D. Srinivasan and K. Raja, “Common Ear, Nose, and Throat Disorders in Childhood,” in Common Childhood Diseases - Diagnosis, Prevention and Management, IntechOpen, 2024. doi: 10.5772/intechopen.1006071. https://doi.org/10.5772/intechopen.1006071
[52] W. Feleszko, M. Ruszczyński, and B. M. Zalewski, “Non-specific immune stimulation in respiratory tract infections. Separating the wheat from the chaff,” Paediatr. Respir. Rev., vol. 15, no. 2, pp. 200–206, Jun. 2014, doi: 10.1016/j.prrv.2013.10.006. https://doi.org/10.1016/j.prrv.2013.10.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Paweł Poniewozik, Maja Pernal, Joanna Mioduszewska, Paweł Rot, Piotr Poniewozik, Natalia Dziuba, Aleksandra Sim, Andrzej Zuzak, Zofia Roguska, Krzysztof Grabowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 2
Number of citations: 0
